These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30396996)

  • 1. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
    Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
    EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Conditional medium of gastric cancer mesenchymal stem cells promotes PD-L1 expression in gastric cancer cells and tumor growth via upregulating VGLL4].
    Ding Y; Zhu W; Wang Q; Chen B; Wang M; Zhao Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):321-327. PubMed ID: 35583061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
    Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
    Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
    Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
    Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
    Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I
    J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
    Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 10. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
    Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.
    Lu M; Wang K; Ji W; Yu Y; Li Z; Xia W; Lu S
    Cell Immunol; 2022 Sep; 379():104577. PubMed ID: 35870429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
    Dorand RD; Nthale J; Myers JT; Barkauskas DS; Avril S; Chirieleison SM; Pareek TK; Abbott DW; Stearns DS; Letterio JJ; Huang AY; Petrosiute A
    Science; 2016 Jul; 353(6297):399-403. PubMed ID: 27463676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
    Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
    J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 16. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.
    Zhang W; Gao Y; Li P; Shi Z; Guo T; Li F; Han X; Feng Y; Zheng C; Wang Z; Li F; Chen H; Zhou Z; Zhang L; Ji H
    Cell Res; 2014 Mar; 24(3):331-43. PubMed ID: 24458094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
    Jiao S; Li C; Hao Q; Miao H; Zhang L; Li L; Zhou Z
    Nat Commun; 2017 Jan; 8():14058. PubMed ID: 28051067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Nuclear Receptor Coactivator SRC-1 Prevents Colorectal Cancer Immune Escape by Reducing Transcription and Protein Stability of PD-L1.
    Hong Y; Chen Q; Wang Z; Zhang Y; Li B; Guo H; Huang C; Kong X; Mo P; Xiao N; Xu J; Ye Y; Yu C
    Adv Sci (Weinh); 2024 Sep; 11(33):e2310037. PubMed ID: 38953362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
    Ni W; Mo H; Liu Y; Xu Y; Qin C; Zhou Y; Li Y; Li Y; Zhou A; Yao S; Zhou R; Huo J; Che L; Li J
    Mol Ther; 2021 Oct; 29(10):2995-3010. PubMed ID: 33992804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.